How will HEOR leaders respond to recent policy changes? A survey from Tufts and the Center for the Evaluation of Value and Risk in Health (CEVR) provides the answer. About 2/3 of the n=57 respondents were Head of their HEOR department and the remaining 1/3 had some other senior level HEOR role. Three key topic include IRA drug price negotiation, PDABs, most favored nation (MFN), and the Institute for Clinical and Economic Review (ICER). What did they find?
A majority (68%) of respondents stated that they somewhat or strongly agreed that the Inflation Reduction Act (IRA) has driven a greater need for HEOR evidence generation (Figure 1). Eleven percent reported that their companies are prioritizing biologics over small molecules in response to the IRA, while 30% reported that their companies are delaying or changing research plans for additional indications…Over half of respondents expect Prescription Drug Affordability Boards (PDABs) to further increase the demand for HEOR (57%) and real-world evidence (RWE) (61%)
About 3 in 10 respondents stated that MFN would delay drug launches in developed countries in the MFN reference basket.
In terms of anticipated behavior regarding “Most-Favored-Nation” (MFN) pricing policies, 29% reported that their companies would delay product launches or increase prices in other developed nations, 27% noted that their companies were lobbying the federal government to abandon MFN proposals, and 39% stated that their companies had taken no action (Figure 3).
Only one in four respondents thought ICER was gaining importance.
Twenty-three percent of respondents strongly or somewhat agreed that the Institute for Clinical and Economic Review (ICER) is gaining importance, while 43% disagreed and 34% were neutral on the matter.
The full report can be read here.
